CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
This article was originally published in Pharmaceutical Approvals Monthly
FDA is seeking public input on cross-cutting policy issues to bring before the senior-level group, which is also facing the challenge of reviewing dozens of “breakthrough therapy” designation requests relevant to CDER-regulated products.
You may also be interested in...
Intra-agency group would be tasked with ensuring consistent use of the expedited pathway across the FDA, with duties potentially including development of best practices, product review team training, and advising on withdrawals, according to the Senate's bipartisan user fee legislation.
Pilot project sets timelines for lead and consulting centers that will feed into more substantial changes in PDUFA VI.
CDER Director Janet Woodcock is creating an executive-level forum to deliberate medical policies, including those needed to smooth drug reviews. She envisions stakeholder input on topics for discussion by the panel.